{"id":57052,"date":"2024-11-07T13:59:28","date_gmt":"2024-11-07T13:59:28","guid":{"rendered":"https:\/?p=57052"},"modified":"2024-11-07T13:59:28","modified_gmt":"2024-11-07T13:59:28","slug":"esperion-therapeutics-q3-financials","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/","title":{"rendered":"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook"},"content":{"rendered":"<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/ESPR\">Esperion Therapeutics Inc (ESPR)<\/a> recently reported its financial results for Q3 2024, showcasing a solid revenue increase and notable developments in its business strategies.<\/p>\n<p>The company has demonstrated substantial growth in prescription volumes and enhanced access to its LDL-C-lowering products, NEXLETOL and NEXLIZET, aiming to bolster its market position within the cardiovascular treatment landscape.<\/p>\n<p>Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor\u2019s premium features. Claim your <a href=\"https:\/\/www.stocktargetadvisor.com\/discover\/end-of-summer-sale\/\">discount<\/a> here!<\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/discover\/end-of-summer-sale\/\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-54446 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/09\/STA-Promotion-Banner-6.png\" alt=\"Promotion Banner\" width=\"2000\" height=\"300\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Promotion-Banner-6.png 2000w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Promotion-Banner-6-300x45.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Promotion-Banner-6-1024x154.png 1024w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Promotion-Banner-6-150x23.png 150w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Promotion-Banner-6-768x115.png 768w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Promotion-Banner-6-1536x230.png 1536w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Promotion-Banner-6-1200x180.png 1200w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/a><\/p>\n<h2>Key Insights from Esperion Therapeutics\u2019 Q3 2024 Earnings Report:<\/h2>\n<ul>\n<li><strong>Revenue Growth:<\/strong> Q3 2024 total revenue reached $51.6 million, a 52% year-over-year increase.<\/li>\n<li><strong>U.S. net product revenue:<\/strong> rose by 53%, totaling $31.1 million.<\/li>\n<li><strong>Momentum in October 2024:<\/strong> Total retail prescription equivalents rose by 17% compared to the start of Q3 2024.<\/li>\n<li><strong>International Expansion:<\/strong> Esperion\u2019s collaboration with DSE has significantly increased royalty revenue from NILEMDO\u00ae and NUSTENDI\u00ae sales across Europe.<\/li>\n<li><strong>Future Market Expansion in Asia:<\/strong> Partner Otsuka Pharmaceutical is on track to file for regulatory approval in Japan by the end of 2024, with potential market entry expected in 2025, broadening Esperion\u2019s presence in the Asian market.<\/li>\n<\/ul>\n<p>Is now the time to buy ESPR? Access our <a href=\"https:\/\/www.stocktargetadvisor.com\/detail_page_report\/Report?symbolstring=ESPR&amp;symbolstringinput=ESPR,QQQ&amp;endDate=undefined&amp;startDate=undefined&amp;hige=1&amp;score=0\">full analysis report here<\/a>, it\u2019s free.<\/p>\n<h2>Management Discussion and Analysis:<\/h2>\n<p>CEO Sheldon Koenig emphasized Esperion\u2019s transformative year, highlighting the successful commercialization initiatives, label expansions, and a reinforced balance sheet after monetizing European royalties. The company\u2019s strategic partnerships, especially with DSE in Europe, are yielding impressive growth in prescription volumes and revenue, a promising indicator of potential success in the U.S. market.<\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/ESPR\"><img decoding=\"async\" class=\"aligncenter wp-image-57054 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/11\/sta-analyst-target-widget-54.png\" alt=\"\" width=\"494\" height=\"295\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/sta-analyst-target-widget-54.png 494w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/sta-analyst-target-widget-54-300x179.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/sta-analyst-target-widget-54-150x90.png 150w\" sizes=\"(max-width: 494px) 85vw, 494px\" \/><\/a><\/p>\n<p>With new Medicare formulary additions and expanded coverage across major U.S. payers, Esperion has positioned NEXLETOL and NEXLIZET for sustained growth. On the R&amp;D front, Q3 saw a 30% decrease in expenses compared to the same period in 2023, primarily due to the completion of the CLEAR Outcomes study, allowing the company to focus on commercial execution.<\/p>\n<p>Discover more <a href=\"https:\/\/www.stocktargetadvisor.com\/top-stocks\">Top-Performing Stocks<\/a> and market insights on Stock Target Advisor to stay ahead in your investment journey.<\/p>\n<h2>Stock Target Advisor\u2019s Analysis on Esperion Therapeutics Inc:<\/h2>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a> offers a mixed outlook on Esperion Therapeutics. While analysts set an average target price of $9.70, rating it as a &#8220;Strong Buy,&#8221; Stock Target Advisor&#8217;s own rating is &#8220;Very Bearish,&#8221; citing six negative signals including poor risk-adjusted returns, negative cash flow, and low revenue growth compared to peers.<\/p>\n<p>The stock recently closed at $2.21, and its 12-month performance showcased a notable 123.03% capital gain, albeit with high volatility and below-average growth over the past five years.<\/p>\n<p>Discover detailed stock and <a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/ESPR\/etfs\">ETF performance<\/a> insights for Esperion Therapeutics Inc here.<\/p>\n<h2>Conclusion:<\/h2>\n<p>Esperion Therapeutics Inc.\u2019s Q3 2024 report reflects the company\u2019s efforts to expand its market reach, enhance product accessibility, and build strategic international partnerships.<\/p>\n<p>As Esperion moves forward with its commercialization and regulatory strategies, the market response and upcoming results from its ongoing initiatives will be key in shaping its financial outlook and stock performance.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Esperion Therapeutics Inc (ESPR) recently reported its financial results for Q3 2024, showcasing a solid revenue increase and notable developments in its business strategies. The&#8230;<\/p>\n","protected":false},"author":17,"featured_media":57057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-57052","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook<\/title>\n<meta name=\"description\" content=\"Esperion Therapeutics reports record Q3 2024 revenue growth of 52% and expanding market potential in Europe, Japan, and beyond\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook\" \/>\n<meta property=\"og:description\" content=\"Esperion Therapeutics reports record Q3 2024 revenue growth of 52% and expanding market potential in Europe, Japan, and beyond\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-07T13:59:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STAs-Blog-Images-94.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1256\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook\",\"datePublished\":\"2024-11-07T13:59:28+00:00\",\"dateModified\":\"2024-11-07T13:59:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/\"},\"wordCount\":490,\"commentCount\":18,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/\",\"name\":\"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-11-07T13:59:28+00:00\",\"dateModified\":\"2024-11-07T13:59:28+00:00\",\"description\":\"Esperion Therapeutics reports record Q3 2024 revenue growth of 52% and expanding market potential in Europe, Japan, and beyond\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook","description":"Esperion Therapeutics reports record Q3 2024 revenue growth of 52% and expanding market potential in Europe, Japan, and beyond","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/","og_locale":"en_US","og_type":"article","og_title":"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook","og_description":"Esperion Therapeutics reports record Q3 2024 revenue growth of 52% and expanding market potential in Europe, Japan, and beyond","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-11-07T13:59:28+00:00","og_image":[{"width":2400,"height":1256,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/11\/STAs-Blog-Images-94.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook","datePublished":"2024-11-07T13:59:28+00:00","dateModified":"2024-11-07T13:59:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/"},"wordCount":490,"commentCount":18,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/","name":"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-11-07T13:59:28+00:00","dateModified":"2024-11-07T13:59:28+00:00","description":"Esperion Therapeutics reports record Q3 2024 revenue growth of 52% and expanding market potential in Europe, Japan, and beyond","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/esperion-therapeutics-q3-financials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Esperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future Outlook"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/57052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=57052"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/57052\/revisions"}],"predecessor-version":[{"id":57058,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/57052\/revisions\/57058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/57057"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=57052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=57052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=57052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}